An antioxidant nanozyme for targeted cardiac fibrosis therapy post myocardial infarction.

ABSTRACT: The excessive release of reactive oxygen species (ROS) after myocardial infarction (MI) disrupts the natural healing process, leading to cardiac fibrosis and compromising patient prognosis. However, the clinical application of many antioxidant drugs for MI treatment is hindered by their poor antioxidant efficacy and inability to specifically target the heart. Here we developed a tannic acid-modified MnO₂ nanozyme (named MnO₂@TA), which can achieve cardiac targeting to inhibit post-MI fibrosis and enhance cardiac function. Specifically, the MnO₂@TA nanozyme, endowed with superoxide dismutase (SOD) and catalase (CAT) activities, effectively scavenges ROS, suppressing fibroblast activation and mitigating cardiac fibrosis without affecting cardiac repair. Notab

SUBMITTER: Gu Z 

PROVIDER: S-EPMC11656654 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature